These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14742192)

  • 1. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.
    Parkin NT; Hellmann NS; Whitcomb JM; Kiss L; Chappey C; Petropoulos CJ
    Antimicrob Agents Chemother; 2004 Feb; 48(2):437-43. PubMed ID: 14742192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.
    Zhang J; Rhee SY; Taylor J; Shafer RW
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):439-44. PubMed ID: 15764961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.
    Choi JY; Kwon OK; Choi SY; Park YK; Kim SS
    J Clin Virol; 2011 Jan; 50(1):19-25. PubMed ID: 20970373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.
    Van Houtte M; Picchio G; Van Der Borght K; Pattery T; Lecocq P; Bacheler LT
    J Med Virol; 2009 Oct; 81(10):1702-9. PubMed ID: 19697398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.
    Chang S; Zhuang D; Li J; Liu S; Li H; Han J; Li L; Liu Y; Bao Z; Li T; Song H; Zhang W
    Int J Infect Dis; 2015 Aug; 37():86-92. PubMed ID: 26117343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
    Borroto-Esoda K; Parkin N; Miller MD
    Antivir Chem Chemother; 2007; 18(5):297-300. PubMed ID: 18046962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.
    Qari SH; Respess R; Weinstock H; Beltrami EM; Hertogs K; Larder BA; Petropoulos CJ; Hellmann N; Heneine W
    J Clin Microbiol; 2002 Jan; 40(1):31-5. PubMed ID: 11773089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients.
    Agwale SM; Zeh C; Paxinos E; Odama L; Pienazek D; Wambebe C; Kalish ML; Ziermann R
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):22-6. PubMed ID: 16438641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
    Harrigan PR; Montaner JS; Wegner SA; Verbiest W; Miller V; Wood R; Larder BA
    AIDS; 2001 Sep; 15(13):1671-7. PubMed ID: 11546942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.
    Saladini F; Giannini A; Boccuto A; Vicenti I; Zazzi M
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28303602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
    Tuaillon E; Gueudin M; Lemée V; Gueit I; Roques P; Corrigan GE; Plantier JC; Simon F; Braun J
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1543-9. PubMed ID: 15577405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
    Harrigan PR; Salim M; Stammers DK; Wynhoven B; Brumme ZL; McKenna P; Larder B; Kemp SD
    J Virol; 2002 Jul; 76(13):6836-40. PubMed ID: 12050397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.
    Derache A; Wallis CL; Vardhanabhuti S; Bartlett J; Kumarasamy N; Katzenstein D
    J Infect Dis; 2016 Jan; 213(2):250-6. PubMed ID: 26175454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
    Zolopa AR; Lazzeroni LC; Rinehart A; Vezinet FB; Clavel F; Collier A; Conway B; Gulick RM; Holodniy M; Perno CF; Shafer RW; Richman DD; Wainberg MA; Kuritzkes DR
    Clin Infect Dis; 2005 Jul; 41(1):92-9. PubMed ID: 15937768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
    Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
    Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.